Generic Name and Formulations:
Cosyntropin 0.25mg/mL; pwd for IV or IM inj after reconstitution; preservative-free.
Amphastar Pharmaceuticals, Inc.
Indications for CORTROSYN:
For use in the screening of patients presumed to have adrenocortical insufficiency.
Adults and Children:
Give by IV, IM inj or IV infusion over 4–8hrs. <2yrs: 0.125mg. ≥2yrs: Usual range: 0.25–0.75mg.
Patients with raised bilirubin or where plasma contains free hemoglobin: falsely high fluorescence measurements may result. Pregnancy (Cat.C). Nursing mothers.
May accentuate the electrolyte loss associated with diuretics. May exhibit abnormally high plasma cortisol levels if patients taking cortisone, hydrocortisone, spironolactone, estrogens.
Hypersensitivity reactions (eg, rare, but possible), bradycardia, tachycardia, hypertension, peripheral edema, rash.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC